دورية أكاديمية
Emerging role of tumor suppressing microRNAs as therapeutics in managing non-small cell lung cancer.
| العنوان: | Emerging role of tumor suppressing microRNAs as therapeutics in managing non-small cell lung cancer. |
|---|---|
| المؤلفون: | Singh S; Department of Biotechnology, School of Bioengineering and Biosciences, Faculty of Technology and Sciences, Lovely Professional University, Phagwara, Punjab 144411, India., Saxena S; Department of Biotechnology, Babasaheb Bhimrao Ambedkar University, Lucknow, India., Sharma H; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India., Paudel KR; Centre for Inflammation, Centenary Institute and the University of Technology Sydney, School of Life Sciences, Faculty of Science, Sydney, New South Wales, Australia., Chakraborty A; Faculty of Biology, Medicine and Health, The University of Manchester, Oxford Road, Manchester M13 9PL, UK; Cardiovascular Disease Program, Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Clayton, VIC 3800, Australia., MacLoughlin R; Aerogen, IDA Business Park, Dangan, Galway H91 HE94, Ireland; School of Pharmacy & Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin D02 YN77, Ireland; School of Pharmacy & Pharmaceutical Sciences, Trinity College, Dublin D02 PN40, Ireland., Oliver BG; Woolcock Institute of Medical Research, University of Sydney, Sydney, New South Wales, Australia; School of Life Sciences, University of Technology Sydney, Ultimo, NSW 2007, Australia., Gupta G; Centre for Global Health Research, Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, India; Centre of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates., Negi P; School of Pharmaceutical Sciences, Shoolini University of Biotechnology and Management Sciences, Solan 173212, India., Singh SK; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India; Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology, Sydney, Ultimo, NSW 2007, Australia. Electronic address: singhsachin23@gmail.com., Dua K; Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology, Sydney, Ultimo, NSW 2007, Australia; Discipline of Pharmacy, Graduate School of Health, University of Technology, Sydney, Ultimo, NSW 2007, Australia. Electronic address: Kamal.Dua@uts.edu.au. |
| المصدر: | Pathology, research and practice [Pathol Res Pract] 2024 Apr; Vol. 256, pp. 155222. Date of Electronic Publication: 2024 Feb 23. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Gustav Fischer Verlag Country of Publication: Germany NLM ID: 7806109 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1618-0631 (Electronic) Linking ISSN: 03440338 NLM ISO Abbreviation: Pathol Res Pract Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Stuttgart : Gustav Fischer Verlag Original Publication: Stuttgart, New York, Fischer. |
| مواضيع طبية MeSH: | Carcinoma, Non-Small-Cell Lung*/therapy , Carcinoma, Non-Small-Cell Lung*/drug therapy , MicroRNAs*/metabolism , Lung Neoplasms*/therapy , Lung Neoplasms*/drug therapy , Small Cell Lung Carcinoma*/genetics, Humans ; Lung/pathology ; Gene Expression Regulation, Neoplastic |
| مستخلص: | Lung cancer (LC) is the second leading cause of death across the globe after breast cancer. There are two types of LC viz. small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC accounts for approximately 85% of all LC cases. NSCLC affects smokers and people who do not smoke and mainly arises in bronchi and peripheral lungs tissue. LC is often characterized by the alterations of key genes such as EGFR, Wnt/β-catenin signaling, ALK, MET, K-Ras and p53 and downstream signaling pathways associated with tumor growth, differentiation, and survival. Numerous miRNAs have been discovered as a result of advances in biotechnology to treat LC. Various miRNAs those have been identified to treat LC include mir-Let7, mir-34a, mir-134, mir-16-1, mir-320a, mir-148a, mir-125a-5p, mir-497, mir-29, mir-133a, and mir-29a-3p. These miRNAs target various signaling pathways that are involved in pathogenesis of LC. However, due to rapid RNAse degradation, quick clearance, and heat instability, associated with necked miRNA leads to less effective therapeutic effect against LC. Therefore, to overcome these challenges nanocarrier loaded with miRNAs have been reported. They have been found promising because they have the capacity to target the tumor as well as they can penetrate the tumors deep due to nanometer size. Some of the clinical trials have been performed using miR-34a and let-7 for the treatment of LC. In the present manuscript we highlight the role miRNAs as well as their nanoparticle in tumor suppression. Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2024 Elsevier GmbH. All rights reserved.) |
| فهرسة مساهمة: | Keywords: EGFR; Lung cancer; MiRNAs; NSCLC; STAT3; Wnt/ β-catenin; p53 |
| المشرفين على المادة: | 0 (MicroRNAs) 0 (MIRN497 microRNA, human) |
| تواريخ الأحداث: | Date Created: 20240307 Date Completed: 20240415 Latest Revision: 20240415 |
| رمز التحديث: | 20240415 |
| DOI: | 10.1016/j.prp.2024.155222 |
| PMID: | 38452582 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1618-0631 |
|---|---|
| DOI: | 10.1016/j.prp.2024.155222 |